Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34

Benzinga Newsdesk www.benzinga.com Neutral 46.1%

Neg 0% Neu 46.1% Pos 0%

Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.